XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others.
Follow-Up Questions
Who is the CEO of XOMA Royalty Corp?
Mr. Owen Hughes is the Chief Executive Officer of XOMA Royalty Corp, joining the firm since 2023.
What is the price performance of XOMA stock?
The current price of XOMA is $37.59, it has increased 0.01% in the last trading day.
What are the primary business themes or industries for XOMA Royalty Corp?
XOMA Royalty Corp belongs to Biotechnology industry and the sector is Health Care
What is XOMA Royalty Corp market cap?
XOMA Royalty Corp's current market cap is $454.5M
Is XOMA Royalty Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for XOMA Royalty Corp, including 3 strong buy, 5 buy, 2 hold, 0 sell, and 3 strong sell
